Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Malik Berhoune

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
The Annals of Pharmacotherapy|October 30, 2008
Therapeutic strategy for treatment of metastatic non-small cell lung cancerMalik Berhoune, Eugeniu Banu, Florian Scotte, et al.
International Journal for Quality in Health Care : Journal of the International Society for Quality in Health Care|December 17, 2008
The application of hazard analysis and critical control points and risk management in the preparation of anti-cancer drugsBrigitte Bonan, Nicolas Martelli, Malik Berhoune, et al.
Journal of Evaluation in Clinical Practice|December 24, 2010
FabAct®: a decision-making tool for the anticipation of the preparation of anticancer drugsBrigitte Bonan, Nicolas Martelli, Malik Berhoune, et al.
Presse Medicale (Paris, France : 1983)|July 24, 2007
[Misoprostol for treating postpartum hemorrhages]Clémence Godard, Malik Berhoune, Eric Bertrand, et al.
European Journal of Cancer (Oxford, England : 1990)|September 27, 2021
Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicitiesSamia Hajem, Stéphane Ederhy, Stéphane Champiat, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
The Annals of Pharmacotherapy|October 30, 2008
Therapeutic strategy for treatment of metastatic non-small cell lung cancerMalik Berhoune, Eugeniu Banu, Florian Scotte, et al.
International Journal for Quality in Health Care : Journal of the International Society for Quality in Health Care|December 17, 2008
The application of hazard analysis and critical control points and risk management in the preparation of anti-cancer drugsBrigitte Bonan, Nicolas Martelli, Malik Berhoune, et al.
Journal of Evaluation in Clinical Practice|December 24, 2010
FabAct®: a decision-making tool for the anticipation of the preparation of anticancer drugsBrigitte Bonan, Nicolas Martelli, Malik Berhoune, et al.
Presse Medicale (Paris, France : 1983)|July 24, 2007
[Misoprostol for treating postpartum hemorrhages]Clémence Godard, Malik Berhoune, Eric Bertrand, et al.
European Journal of Cancer (Oxford, England : 1990)|September 27, 2021
Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicitiesSamia Hajem, Stéphane Ederhy, Stéphane Champiat, et al.
Pageof 1